DOI: http://dx.doi.org/10.18203/2349-3933.ijam20151251

Primary systemic chemotherapy in locally advanced breast cancer- taxane versus non-taxane combination chemotherapy schedule

Aravindh S. Anand, Biju U. Francis

Abstract


Background: Primary systemic chemotherapy (PST) forms a pivotal role in the management of primarily inoperable locally advanced breast cancer (LABC). Studies have revealed that complete pathologic response (pCR) is a surrogate marker of survival of LABC patients. In this study we aim to compare two chemotherapy regimens TAC vs. FAC/FEC. Endpoints are pCR and toxicity.

Methods: 130 primarily inoperable LABC patients who received PST with either taxane containing chemotherapy TAC (Docetaxe l75 mg/m2, Adriamycin 50 mg/m2, Cyclophosphamide 500 mg/m2) or non-taxane chemotherapy FAC (5-Flurouracil 500 mg/m2, Adriamycin 50 mg/m2, Cyclophosphamide 500 mg/m2)/FEC (5-Flurouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) were prospectively observed and studied as two treatment arms- Taxane arm (70 patients) or Non-taxane arm (60 patients). Patients in each arm received maximum 6 cycles of taxane or non-taxane chemotherapy. Tumor response & toxicity was assessed.

Results: 25.7% patients in taxane arm and 10% patients in non-taxane arm had complete pathological response (p=0.014). 90% in taxane arm and 86.7% in non-taxane arm became operable after PST (p=0.564). Grade 3 or 4 neutropenia was seen in 45.7% and 3.3% in Taxane and non-Taxane arm respectively (p=0.000). All patients completed the planned treatment in spite of the higher incidence of Grade 3/4 neutropenia in the docetaxel arm.

Conclusions:TAC has significantly better complete pathologic response with tolerable toxicity. Hence in Indian LABC patients as well, taxane containing chemotherapy in the primary setting is the better option. Longer follow up of this study may confirm whether the better pathologic response may translate to better survival.


Keywords


Locally advanced breast cancer, Tumor response, Taxane

Full Text:

PDF

References


Information by type of cancer, Tata Memorial Hospital. Available at www.tmc.gov.in, 2014.

National Center for Biotechnology Information; www.ncbi.nlm.nih.gov.

Symmans WF, Peintinger F, Hatzis C. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol. 2007;25:4414-22.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. Eur J Cancer. 2009;45(2):228-47.

NCI Common Toxicity Criteria version 2.

Bear HD, Anderson S, Brown A. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-74.

Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India: A study of 798 tumors. Breast. 2000;9:267-70.

Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, et al. Hormone receptors over the last 8 years in a cancer referral center in India: What was and what is? Indian J Pathol Microbiol. 2009;52:171-4.

Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS. Weekly paclitaxel plus carboplatin is an effective non anthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2010;21:961-7.

Von Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, Jackisch C, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol. 1999;17:1999-2005.

Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol. 1999;17:3033-7.

Malhotra V, Dorr VJ, Lyss AP, Anderson CM, Westgate S, Reynolds M, et al. Neoadjuvant and adjuvant chemotherapy (CT) with doxorubicin and docetaxel (DD) with surgery and radiation in locally advanced breast cancer. Proc Am Soc Clin Oncol. 1999;2:b6.

Valero V, Esteva FJ, Sahin AA, Booser DJ, Strom EA, Esparza-Guerra LT, et al. Phase II trial of neoadjuvant chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy ± tamoxifen in locally advanced breast cancer. Breast Cancer Res Treat. 2000;64:69.

Bouzid K, Vinholes J, Salas F, Mickiewicz E, Valdivia S, Ostapenko V, et al. A Phase III trial of Taxotere and doxorubicin (AT) vs. 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: An interim analysis. Eur J Cancer. 2010;37:s167.

von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast. A randomized, controlled, open phase IIb study. J Clin Oncol. 2001;19:3506-15.

Bines J, Vinholes J, Del Giglio A, Vasconcelos A, Cabral C, Gusmao C, et al. Neo-adjuvant chemotherapy with weekly docetaxel (taxotere) in poor prognosis locally-advanced breast cancer (LABC). Breast Cancer Res Treat. 2002;76:s54.

Andrade JM, Carrara HH, Pimentel FF, Marana HR, Macchetti AH, Mouro LR, et al. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer. Med Oncol, 2010.

Omidvari S, Hosseini S, Ashouri Y, Tahmasebi S, Talei A, Nasrolahi H, et al. Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial Middle East Journal of Cancer. 2011;2(2):51-8.